TW369521B - Androstenone derivative - Google Patents

Androstenone derivative

Info

Publication number: TW369521B
Authority: TW; Taiwan
Prior art keywords: preparation; androstenone; derivative; androstenone derivative; 5alpha
Prior art date: 1993-09-17

Application number

TW083108127A

Other languages

English (en)

Inventor

Kenneth William Batchelor

Stephen Vernon Frye

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-17

Filing date

1994-09-03

Publication date

1999-09-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22407744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW369521(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-09-03 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

1999-09-11 Application granted granted Critical

1999-09-11 Publication of TW369521B publication Critical patent/TW369521B/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/82—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
- C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
- C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/14—Benz[f]indenes; Hydrogenated benz[f]indenes

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

TW083108127A 1993-09-17 1994-09-03 Androstenone derivative TW369521B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US12328093A	1993-09-17	1993-09-17

Publications (1)

Publication Number	Publication Date
TW369521B true TW369521B (en)	1999-09-11

Family

ID=22407744

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW083108127A TW369521B (en)	1993-09-17	1994-09-03	Androstenone derivative

Country Status (41)

Country	Link
US (2)	US5565467A (zh)
EP (1)	EP0719278B1 (zh)
JP (1)	JP2904310B2 (zh)
KR (1)	KR100364953B1 (zh)
CN (1)	CN1057771C (zh)
AP (1)	AP494A (zh)
AT (1)	ATE162199T1 (zh)
AU (1)	AU690925B2 (zh)
BG (1)	BG62363B1 (zh)
BR (1)	BR1100329A (zh)
CA (2)	CA2170047C (zh)
CY (2)	CY2219B1 (zh)
CZ (1)	CZ286069B6 (zh)
DE (2)	DE10399022I2 (zh)
DK (1)	DK0719278T3 (zh)
EE (1)	EE03241B1 (zh)
ES (1)	ES2113127T3 (zh)
FI (1)	FI115216B (zh)
GR (1)	GR3026144T3 (zh)
HK (1)	HK1004334A1 (zh)
HR (1)	HRP940563B1 (zh)
HU (1)	HU220060B (zh)
IL (1)	IL110978A (zh)
IS (1)	IS1713B (zh)
LU (1)	LU91027I2 (zh)
MY (1)	MY119778A (zh)
NL (1)	NL300122I2 (zh)
NO (2)	NO306117B1 (zh)
NZ (1)	NZ274642A (zh)
OA (1)	OA10575A (zh)
PE (1)	PE15095A1 (zh)
PL (1)	PL180002B1 (zh)
RO (1)	RO117455B1 (zh)
RU (1)	RU2140926C1 (zh)
SA (1)	SA94150231B1 (zh)
SG (1)	SG52650A1 (zh)
SI (1)	SI0719278T1 (zh)
SK (1)	SK281869B6 (zh)
TW (1)	TW369521B (zh)
WO (1)	WO1995007927A1 (zh)
ZA (2)	ZA947119B (zh)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH07508033A (ja) *	1992-05-20	1995-09-07	メルク　エンド　カンパニー　インコーポレーテッド	５α−レダクターゼ阻害剤としての３−オキソ−４−アザステロイドの新規１７−エステル，アミド及びケトン誘導体
DE69329933T2 (de) *	1992-10-06	2001-07-19	Merck & Co., Inc.	17-beta-carboxanilid derivate von 4-aza-5-alpha-androstan-3-one als 5-alpha-reduktase-hemmende arzneimittel
TW408127B (en) *	1993-09-17	2000-10-11	Glaxo Inc	Androstenones
US5547957A (en) *	1993-10-15	1996-08-20	Merck & Co., Inc.	Method of treating androgenic alopecia with 5-α reductase inhibitors
TW382595B (en) *	1993-10-15	2000-02-21	Merck & Co Inc	Pharmaceutical composition for use in arresting and reversing androgenic alopecia
DE69415824T2 (de) *	1993-10-21	1999-08-05	Merck & Co., Inc., Rahway, N.J.	16-substituierte-4-aza-androstan-5-alpha-reduktase-isozym-i-inhibitoren
US5817818A (en) *	1994-09-16	1998-10-06	Glaxo Wellcome Inc.	Androstenones
US6001844A (en) *	1995-09-15	1999-12-14	Merck & Co., Inc.	4-Azasteroids for treatment of hyperandrogenic conditions
US5872126A (en) *	1996-09-06	1999-02-16	Merck & Co., Inc.	Methods and compositions for treating preterm labor
US5935968A (en) *	1997-03-17	1999-08-10	Merck & Co., Inc.	Methods for treating polycystic ovary syndrome
GB9717428D0 (en) *	1997-08-19	1997-10-22	Glaxo Group Ltd	Pharmaceutical composition
EP1032400A4 (en) *	1997-10-28	2006-04-12	Merck & Co Inc	PREVENTION OF SUDDEN ACUTE URINRETENTION
BR9908592A (pt) *	1998-03-11	2001-04-24	Endorech Inc	Processo para inibir a atividade de 17ß-hidroxiesteróide desidrogenase tipo 5, composição farmacêutica, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 5, processo para inibir 17ß-hidroxiesteróide desidrogenase tipo 3, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 3, processos para tratar, ou reduzir o risco de desenvolver, câncer da próstata, hiperplasia prostática benigna, acne, seborréia, hirsutismo ou alopécia androgênica, sìndrome de ovário policìstico, câncer de mama, endometriose ou leiomioma, para inibir as secreções hormonais testiculares, para tratar puberdade precoce, e, kit
EP1321146A3 (en) *	1998-03-11	2004-06-02	Endorecherche Inc.	Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
US5998427A (en) *	1998-05-14	1999-12-07	Glaxo Wellcome Inc.	Androstenones
WO1999066915A2 (en) *	1998-06-23	1999-12-29	Southern Illinois University At Carbondale	Therapeutic applications of estrogenic carboxylic acids
AU2512800A (en) *	1999-02-03	2000-08-25	Eli Lilly And Company	Alpha1-adrenergic receptor antagonists
BR0010708A (pt)	1999-05-04	2002-02-19	Strakan Ltd	Glicosìdeos androgênicos e atividade androgênica dos mesmos
US6645974B2 (en)	2001-07-31	2003-11-11	Merck & Co., Inc.	Androgen receptor modulators and methods for use thereof
WO2003029268A1 (en) *	2001-10-03	2003-04-10	Merck & Co., Inc.	Androstane 17-beta-carboxamides as androgen receptor modulators
ES2297123T3 (es) *	2002-01-25	2008-05-01	Asahi Glass Company Ltd.	Procedimiento para producir 2,5-bis(trifluorometil)nitribenceno.
JP2005524693A (ja) *	2002-04-24	2005-08-18	ベーリンガーインゲルハイムファルマゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフト	良性前立腺増殖症の治療又は急性尿閉の長期予防用の医薬組成物
AU2003223754B2 (en) *	2002-04-30	2007-08-16	Merck Sharp & Dohme Corp.	4-azasteroid derivatives as androgen receptor modulators
US7326717B2 (en) *	2003-05-06	2008-02-05	L'oreal	Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof
US7022854B2 (en) *	2003-07-17	2006-04-04	Dr. Reddy's Laboratories, Limited	Forms of dutasteride and methods for preparation thereof
US20050059692A1 (en) *	2003-09-09	2005-03-17	Dr. Reddy's Laboratories Limited	Process for the preparation of 17beta-N-[2,5-bis(trifluoromethyl)phenyl] carbamoyl-4-aza-5-alpha-androst-1-en-3-one
EP1746998A1 (en) *	2004-03-22	2007-01-31	Ranbaxy Laboratories, Ltd.	Combination therapy for lower urinary tract symptoms
EP1734963A4 (en)	2004-04-02	2008-06-18	Merck & Co Inc	METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
CN101005841A (zh) *	2004-08-25	2007-07-25	默克公司	雄激素受体调节剂
EP1824495A2 (en) *	2004-12-03	2007-08-29	ProteoSys AG	Finasteride, dutasteride and related compounds for preventing/treating neurologically-associated disorders
US20060193804A1 (en) *	2005-02-24	2006-08-31	L'oreal	Haircare use of cyclic amine derivatives
AU2006229840B2 (en)	2005-03-25	2010-12-23	Merck Sharp & Dohme Corp.	Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
WO2007120263A2 (en) *	2005-11-10	2007-10-25	Dr. Reddy's Laboratories Ltd.	Preparation of dutasteride
EP1897533A1 (en) *	2006-09-08	2008-03-12	Revotar Biopharmaceuticals AG	Use of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha -D-mannopyranosyl-oxy)-phenyl] hexane for the preparation of cosmetic compositions
EP1946756A1 (en) *	2007-01-17	2008-07-23	Revotar Biopharmaceuticals AG	Use of entacapone in cosmetic, dermatological and pharmaceutical compositions
FR2920309B1 (fr)	2007-08-28	2010-05-28	Galderma Res & Dev	Utilisation de travoprost pour traiter la chute des cheveux
US20090076057A1 (en) *	2007-09-13	2009-03-19	Protia, Llc	Deuterium-enriched dutasteride
EP2050436A1 (en)	2007-12-21	2009-04-22	Siegfried Generics International AG	Pharmaceutical composition containing dutasteride
AR070313A1 (es) *	2008-01-03	2010-03-31	Gador Sa	Un procedimiento para preparar una forma solida y cristalina de dutasteride, una forma polimorfica del compuesto (forma iii) y una composicion farmaceutica que incluye dicha forma
FR2929117B1 (fr)	2008-03-28	2010-05-07	Oreal	Utilisation de l'association du 2,4-diaminopyrimidine 3-n-oxyde et du madecassosside et/ou du terminoloside pour induire et/ou stimuler la croissance de ces fibres keratiniques humaines et/ou freiner leur chute
FR2929118B1 (fr)	2008-03-28	2010-05-07	Oreal	Utilisation de l'association de madecassoside et/ou de terminoloside et d'une arginine pour induire et/ou stimuler la croissance de ces fibres keratiniques humaines et/ou freiner leur chute
CN102215845A (zh)	2008-04-03	2011-10-12	哈博生物科学公司	药学试剂的固体形式
US20100048598A1 (en) *	2008-08-21	2010-02-25	Sateesh Kandavilli	Topical compositions comprising 5-alpha reductase inhibitors
CN101759762B (zh) *	2008-11-06	2013-03-20	天津金耀集团有限公司	4ad在制备度他雄胺中的应用
WO2011004242A2 (en) *	2009-07-09	2011-01-13	Aurobindo Pharma Limited	An improved process for the preparation of dutasteride
FR2949052B1 (fr)	2009-08-13	2015-03-27	Oreal	Procede de traitement cosmetique du cuir chevelu.
EP2468262A1 (en)	2010-12-06	2012-06-27	Krka Tovarna Zdravil, D.D., Novo Mesto	Pharmaceutical composition comprising dutasteride
WO2012162776A1 (pt) *	2011-06-03	2012-12-06	Eurofarma Laboratórios S.A	Composição farmacêutica para o tratamento de hiperplasia prostática benigna
HU230730B1 (hu)	2011-06-30	2017-12-28	Richter Gedeon Nyrt	Eljárás (5alfa,17béta)-N-[2,5-bisz-(trifluormetil)-fenil]-3-oxo-4-aza-5-androszt-1-én-17-karbonsavamid előállítására
CN103059098B (zh) *	2011-10-24	2015-04-01	成都国为医药科技有限公司	一种度他雄胺的制备方法
US9622981B2 (en)	2011-11-17	2017-04-18	Mylan Inc.	Liquid-filled hard gel capsule pharmaceutical formulations
CN102382165B (zh) *	2011-12-02	2014-05-07	华润赛科药业有限责任公司	一种度他雄胺的制备方法
CN103554210A (zh) *	2012-01-05	2014-02-05	中国药科大学	甾体类5α-还原酶抑制剂、其制备方法及其医药用途
CN102532236B (zh) *	2012-01-05	2014-04-16	中国药科大学	甾体类5α-还原酶抑制剂、其制备方法及其医药用途
KR101976137B1 (ko)	2012-01-25	2019-05-09	한미약품 주식회사	두타스테라이드 함유 자가 유화 약물전달 시스템용 조성물 및 이의 제조 방법
CA2870666A1 (en)	2012-04-16	2013-10-24	Case Western Reserve University	Compositions and methods of modulating 15-pgdh activity
WO2014002015A1 (en)	2012-06-25	2014-01-03	Ranbaxy Laboratories Limited	Pharmaceutical composition comprising dutasteride
HK1220356A1 (zh) *	2013-03-14	2017-05-05	Pellficure Pharmaceuticals, Inc.	用於前列腺癌的新颖疗法
CN103254268A (zh) *	2013-05-16	2013-08-21	寿光市富康化学工业有限公司	一种制备度他雄胺的工艺
BR102013020508B1 (pt)	2013-08-12	2021-01-12	Ems S/A.	Forma de dosagem que compreende um inibidor de esteroide 5-alfa-redutase e um bloqueador alfa, processo para a preparaçãode uma forma de dosagem e uso da forma de dosagem
JP6517197B2 (ja)	2013-10-15	2019-05-22	ケースウエスタンリザーブユニバーシティ	短鎖デヒドロゲナーゼ活性を調節する組成物および方法
ES2555485T1 (es)	2014-05-26	2016-01-04	Galenicum Health S.L.	Composiciones farmacéuticas que contienen un agente activo
US11351155B2 (en)	2014-12-05	2022-06-07	Case Western Reserve University	Compositions and methods of modulating s-nitrosylation
KR101590072B1 (ko)	2014-12-23	2016-01-29	한미약품 주식회사	두타스테라이드를 포함하는 자가유화 약물전달 시스템용 조성물
BR112017019446A2 (pt) *	2015-03-13	2018-04-24	Dow Global Technologies Llc	complexo de cromo com um ligante contendo fosfaciclo e catalisador de oligomerizacão de olefina do mesmo
KR102503428B1 (ko)	2015-12-22	2023-02-24	한미약품 주식회사	두타스테라이드를 포함하는 경구용 연질 캡슐 제형용 포장재
KR101968754B1 (ko)	2016-03-16	2019-04-12	한미약품 주식회사	두타스테라이드 및 탐수로신 함유 경질 캡슐 복합제 및 그 제조방법
KR101716878B1 (ko)	2016-05-12	2017-03-15	주식회사 유유제약	글리세롤 지방산에스테르유도체 또는 프로필렌글리콜 지방산에스테르유도체를 함유한 두타스테리드와 타다라필의 복합 캡슐제제 조성물 및 이의 제조방법
EP3548035A4 (en)	2016-11-30	2020-07-22	Case Western Reserve University	COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
NZ755890A (en)	2017-02-06	2025-12-19	Univ Case Western Reserve	Compositions and methods of modulating short-chain dehydrogenase activity
EP3677253A4 (en)	2017-09-01	2020-11-04	JW Pharmaceutical Corporation	SOLID PREPARATION INCLUDING DUTASTERIDE AND RELATED PREPARATION PROCESS
KR101996597B1 (ko)	2017-10-13	2019-07-31	주식회사 유유제약	두타스테리드와 타다라필을 용해시킨 경구용 캡슐 제형의 복합제제
KR102281252B1 (ko)	2018-05-21	2021-07-23	(주)인벤티지랩	두타스테라이드를 포함하는 마이크로 입자 및 이의 제조 방법
WO2019225924A1 (ko) *	2018-05-21	2019-11-28	(주)인벤티지랩	두타스테라이드를 포함하는 마이크로 입자 및 이의 제조 방법
AU2019384821B2 (en)	2018-11-21	2025-09-18	Board Of Regents Of The University Of Texas System	Compositions and methods of modulating short-chain dehydrogenase activity
KR20200074759A (ko)	2018-12-17	2020-06-25	동국제약 주식회사	두타스테라이드를 함유하는 고형제제
JP2023527279A (ja)	2020-05-20	2023-06-28	ロデオ・セラピューティクス・コーポレイション	短鎖デヒドロゲナーゼ活性を調節する組成物及び方法
WO2024144084A1 (ko) *	2022-12-26	2024-07-04	주식회사 유영제약	주 1회 투여를 위한 정제 형태의 고함량 두타스테리드 약제학적 조성물 및 이의 제조방법

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4377584A (en) *	1978-04-13	1983-03-22	Merck & Co., Inc.	4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
US4191759A (en) *	1978-04-13	1980-03-04	Merck & Co., Inc.	N-substituted-17β-carbamoylandrost-4-en-3-one 5α reductase inhibitors
AU527030B2 (en) *	1978-04-13	1983-02-10	Merck & Co., Inc.	4-aza-17-substituted-5a-androstan-3-ones
US4220775A (en) *	1979-03-15	1980-09-02	Merck & Co., Inc.	Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
US4317817A (en) *	1979-08-27	1982-03-02	Richardson-Merrell Inc.	Novel steroid 5α-reductase inhibitors
DK465481A (da) *	1980-11-21	1982-05-22	Hoffmann La Roche	Fremgangsmaade til fremstilling af d-homostemoider
US5049562A (en) *	1984-02-27	1991-09-17	Merck & Co., Inc.	17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors
ATE67503T1 (de) *	1984-02-27	1991-10-15	Merck & Co Inc	17-beta-substituierte-4-aza-5-alpha-androstenon und ihre anwendung als 5-alpha-reduktaseinhibitoren.
US4760071A (en) *	1984-02-27	1988-07-26	Merck & Co., Inc.	17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
NZ211145A (en) *	1984-02-27	1988-10-28	Merck & Co Inc	4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
GB8505862D0 (en) *	1985-03-07	1985-04-11	Erba Farmitalia	Steroidic 5alpha-reductase inhibitors
US4845104A (en) *	1986-11-20	1989-07-04	Merck & Co., Inc.	Oxidized analogs of 17β-N-monosubstituted-carbamoyl-4-aza-5-α-androstan-3-ones
ATE78827T1 (de) *	1986-11-20	1992-08-15	Merck & Co Inc	Topisches arzneimittel enthaltend 17-beta-methoxy-carbonyl-4-methyl-4-aza-5-alpha androst-1-en-3- one.
US4888336A (en) *	1987-01-28	1989-12-19	Smithkline Beckman Corporation	Steroid 5-alpha-reductase inhibitors
US5110939A (en) *	1987-01-28	1992-05-05	Smithkline Beecham Corporation	Intermediates in the preparation of steriod 5-alpha-reductase inhibitors
US4814324A (en) *	1987-03-06	1989-03-21	Merck & Co., Inc.	Sterol inhibitors of testosterone 5α-reductase
DE3888378T2 (de) *	1987-04-03	1994-09-29	Merck & Co Inc	Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
EP0285382B1 (en) *	1987-04-03	1994-04-13	Merck & Co. Inc.	Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones
ZA883034B (en) *	1987-04-29	1989-03-29	Smithkline Beckman Corp	Steroid 5-alpha-reductase inhibitors
US5041433A (en) *	1987-04-29	1991-08-20	Smithkline Beecham Corporation	11-keto or hydroxy 3,5-diene steroids as inhibitors of steriod 5-α-reductase
US4910226A (en) *	1987-04-29	1990-03-20	Smithkline Beckman Corporation	Steroid 5-alpha-reductase inhibitors
NZ225100A (en) *	1987-06-29	1991-09-25	Merck & Co Inc	Reaction of steroids (including 4-azasteroids) with a silylating agent in the presence of a quinone to introduce a delta' double bond and silylated intermediates
JP2675418B2 (ja) *	1988-05-25	1997-11-12	スミスクライン・ベックマン・コーポレイション	芳香族ステロイド５‐α‐レダクターゼ抑制剤
US4954446A (en) *	1988-05-25	1990-09-04	Smithkline Beecham Corporation	Aromatic steroid 5-α-reductase inhibitors
US5237061A (en) *	1988-10-31	1993-08-17	Merck & Co., Inc.	Methods of synthesizing benign prostatic hypertropic agents and their intermediates
US4937237A (en) *	1988-12-23	1990-06-26	Smithkline Beckman Corporation	Phosphinic acid substituted aromatic steroids as inhibitors of steroid 5-60 -reductase
US4882319A (en) *	1988-12-23	1989-11-21	Smithkline Beckman Corporation	Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
US4970205A (en) *	1988-12-23	1990-11-13	Smithkline Beecham Corporation	Sulfonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
US4946834A (en) *	1988-12-23	1990-08-07	Smithkline Beecham Corporation	Phosphonic acid substituted steroids as steroid 5α-reductase inhibitors
US5026882A (en) *	1988-12-23	1991-06-25	Smithkline Beecham Corporation	Phosphinic acid substituted steroids as inhibitors of steroid 5α-reductase
US4966898A (en) *	1989-08-15	1990-10-30	Merrell Dow Pharmaceuticals Inc.	4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US4966897A (en) *	1989-08-15	1990-10-30	Merrell Dow Pharmaceuticals Inc.	4-substituted 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
CA2023157A1 (en) *	1989-08-21	1991-02-22	Gary H. Rasmusson	17 beta-acyl-4-aza-5 alpha-androst-1-ene-3-ones as 5 alpha-reductase inhibitors
US5032586A (en) *	1989-08-24	1991-07-16	Smithkline Beecham Corporation	7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha reductase
US5021575A (en) *	1989-11-13	1991-06-04	Merck & Co., Inc.	Method for introducing a 1,2 double bond into azasteroids
US5100917A (en) *	1989-12-29	1992-03-31	Merrell Dow Pharmaceuticals Inc.	Novel a-nor-steroid-3-carboxylic acid derivatives
GB9002922D0 (en) *	1990-02-09	1990-04-04	Erba Carlo Spa	17 beta-substituted-4-aza-5 alpha-androstan-3-one derivatives and process for their preparation
EP0462664A3 (en) *	1990-06-20	1992-11-25	Merck & Co. Inc.	Specific 17beta-thiobenzoyl-4-aza-5alpha-androst-1-en-3-ones as antiandrogenic agents
US5061802A (en) *	1990-06-20	1991-10-29	Merck & Co. Inc.	17β-aminobenzoyl-4-aza-5α-androst-1-en-3-ones as benign prostatic hypertrophy agents
EP0462662A3 (en) *	1990-06-20	1992-08-19	Merck & Co. Inc.	17beta-n-monosubstituted adamantyl/norbornanyl carbamoyl-4-aza-5alpha-androst-1-en-3-ones and androstan-3-ones
US5098908A (en) *	1990-06-20	1992-03-24	Merck & Co., Inc.	17β-hydroxybenzoyl-4-aza-5α-androst-1-en-3-ones as testosterone reductase inhibitors
EP0462665A3 (en) *	1990-06-20	1993-06-30	Merck & Co. Inc.	Selected 17beta-polyaroyl-4-aza-5alpha-androst-1-en-3-ones as steroidal reductase inhibitors
AU637247B2 (en) *	1990-08-01	1993-05-20	Merrell Dow Pharmaceuticals Inc.	4-amino-delta4-steroids and their use as 5alpha-reductase inhibitors
US5318961A (en) *	1990-08-01	1994-06-07	Merrell Dow Pharmaceuticals Inc.	4-amino-Δ4-steroids and their use as 5α-reductase inhibitors
AU642757B2 (en) *	1990-08-01	1993-10-28	Merrell Dow Pharmaceuticals Inc.	4-amino-delta4, 6-steroids and their use as 5alpha-reductase inhibitors
US5120847A (en) *	1990-08-27	1992-06-09	Merck & Co., Inc.	Process for iodinating or brominating the α-methylenic carbon of a secondary amide
US5091534A (en) *	1990-08-27	1992-02-25	Merck & Co., Inc.	Trialkylsilyl trifluoromethanesulfonate mediated α-methylenic carbon functionalization of 4-AZA-5α-androstan-3-one steroids
US5061803A (en) *	1990-09-24	1991-10-29	Merck & Co., Inc.	Process for making 17-beta alkanoyl 3-oxo-4-aza-5-α-androst-1-enes
US5061801A (en) *	1990-09-24	1991-10-29	Merck & Co., Inc.	Intermediate for making 3-oxo-4-aza-androst-1-ene 17β-ketones
CA2050824A1 (en) *	1990-09-24	1992-03-25	John M. Williams	Process for making 3-oxo-4-aza-androst-1-ene 17-.beta.-ketones
IE76452B1 (en) *	1990-10-29	1997-10-22	Sankyo Co	Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use
NZ241979A (en) *	1991-03-20	1996-01-26	Merck & Co Inc	Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
IL101245A0 (en) *	1991-03-20	1992-11-15	Merck & Co Inc	Pharmaceutical compositions for the treatment of prostatic cancer
WO1992018132A1 (en) *	1991-04-17	1992-10-29	Merck & Co., Inc.	Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
GB9115676D0 (en) *	1991-07-19	1991-09-04	Erba Carlo Spa	Process for the preparation of 17 beta substituted-4-aza-5 alpha-androstan-3-one derivatives
US5304562A (en) *	1991-10-09	1994-04-19	Ciba-Geigy Corporation	17β-substituted Aza-androstane derivatives
DE69225244T2 (de) *	1991-12-20	1998-09-24	Glaxo Wellcome Inc	Inhibitoren von testosteron-5-alpha reductase.
JP3164389B2 (ja) *	1991-12-25	2001-05-08	三共株式会社	４−アザステロイド類
JPH07508032A (ja) *	1992-05-20	1995-09-07	メルク　エンド　カンパニー　インコーポレーテッド	５α−レダクターゼ阻害剤としての新規Δ−１７−及びΔ−２０オレフィン性並びに飽和１７β−置換４−アザ−５α−アンドロスタン−オン
DE69329149T2 (de) *	1992-05-20	2001-03-29	Merck & Co., Inc.	4-azasteroide als 5-alpha-reduktase
EP0649306B1 (en) *	1992-05-20	2001-01-10	Merck & Co. Inc.	Ester derivatives of 4-aza-steroids
JPH07508033A (ja) *	1992-05-20	1995-09-07	メルク　エンド　カンパニー　インコーポレーテッド	５α−レダクターゼ阻害剤としての３−オキソ−４−アザステロイドの新規１７−エステル，アミド及びケトン誘導体
WO1993023040A1 (en) *	1992-05-20	1993-11-25	Merck & Co., Inc.	17-ethers and thioethers of 4-aza-steroids
WO1993023420A1 (en) *	1992-05-20	1993-11-25	Merck & Co., Inc.	NEW 7β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS
FI945442A7 (fi) *	1992-05-20	1994-11-18	Merck & Co Inc	Uudet 7beta-substituoidut 4-atsa-5alfa-kolestanonit 5alfa-reduktaasi-i nhibiittoreina
WO1993023039A1 (en) *	1992-05-20	1993-11-25	Merck & Co., Inc.	Substituted 4-aza-5a-androstan-ones as 5a-reductase inhibitors
JPH07508034A (ja) *	1992-05-20	1995-09-07	メルク　エンド　カンパニー　インコーポレーテッド	１７−アミノ置換４−アザステロイド５α−レダクターゼ阻害剤
EP0641211A1 (en) *	1992-05-21	1995-03-08	Endorecherche Inc.	INHIBITORS OF TESTOSTERONE 5$g(a)-REDUCTASE ACTIVITY
GB9210880D0 (en) *	1992-05-21	1992-07-08	Smithkline Beecham Corp	Compounds
GB9216284D0 (en) *	1992-07-31	1992-09-16	Erba Carlo Spa	Fluorinated 17beta-substituted 4-aza-5alpha-androstane-3-one derivatives
GB9216329D0 (en) *	1992-07-31	1992-09-16	Erba Carlo Spa	17beta-substituted 4-aza-5alpha-androstan-3-one derivatives
HU212459B (en) *	1992-10-02	1996-06-28	Richter Gedeon Vegyeszet	Process for producing new 17-beta-substituted 4-aza-androstane-derivatives and pharmaceutical compositions containing them
US5278159A (en) *	1992-10-06	1994-01-11	Merck & Co., Inc.	Aryl ester derivatives of 3-oxo-4-aza-androstane 17-β-carboxylates as 5-α-reductase inhibitors
DE69329933T2 (de) *	1992-10-06	2001-07-19	Merck & Co., Inc.	17-beta-carboxanilid derivate von 4-aza-5-alpha-androstan-3-one als 5-alpha-reduktase-hemmende arzneimittel
AP9300589A0 (en) *	1992-11-18	1994-01-31	Smithkline Beecham Corp	Novel 17a and 17b substituted acyl-3-carboxy 3,5-diene steroidal compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-a-reductase.
AP459A (en) *	1992-12-18	1996-02-14	Glaxo Wellcome Inc	Substituted 6-azaandrostenones.
US5380728A (en) *	1993-02-10	1995-01-10	Merck & Co., Inc.	Aldehyde metabolite of 17β-N-monosubstituted-carbamoyl-4-aza-5α-a
US5438061A (en) *	1993-07-16	1995-08-01	Merck & Co., Inc.	7-substituted-δ4-6-azasteroid derivatives as 5α-reductase inhibitors
TW408127B (en) *	1993-09-17	2000-10-11	Glaxo Inc	Androstenones

1994
- 1994-09-03 TW TW083108127A patent/TW369521B/zh active
- 1994-09-13 IS IS4205A patent/IS1713B/is unknown
- 1994-09-14 MY MYPI94002449A patent/MY119778A/en unknown
- 1994-09-15 ZA ZA947119A patent/ZA947119B/xx unknown
- 1994-09-15 ZA ZA947118A patent/ZA947118B/xx unknown
- 1994-09-15 PE PE1994250737A patent/PE15095A1/es not_active Application Discontinuation
- 1994-09-15 AP APAP/P/1994/000669A patent/AP494A/en active
- 1994-09-16 CZ CZ1996745A patent/CZ286069B6/cs not_active IP Right Cessation
- 1994-09-16 IL IL11097894A patent/IL110978A/en active Protection Beyond IP Right Term
- 1994-09-16 RU RU96108410A patent/RU2140926C1/ru active
- 1994-09-16 DK DK94929828T patent/DK0719278T3/da active
- 1994-09-16 NZ NZ274642A patent/NZ274642A/en not_active IP Right Cessation
- 1994-09-16 AT AT94929828T patent/ATE162199T1/de active
- 1994-09-16 DE DE10399022C patent/DE10399022I2/de active Active
- 1994-09-16 HK HK98103307A patent/HK1004334A1/zh not_active IP Right Cessation
- 1994-09-16 CA CA002170047A patent/CA2170047C/en not_active Expired - Lifetime
- 1994-09-16 AU AU78751/94A patent/AU690925B2/en not_active Expired
- 1994-09-16 CA CA002462061A patent/CA2462061A1/en not_active Abandoned
- 1994-09-16 SI SI9430130T patent/SI0719278T1/xx unknown
- 1994-09-16 JP JP7509391A patent/JP2904310B2/ja not_active Expired - Lifetime
- 1994-09-16 DE DE69407978T patent/DE69407978T2/de not_active Expired - Lifetime
- 1994-09-16 EE EE9600130A patent/EE03241B1/xx unknown
- 1994-09-16 CN CN94193410A patent/CN1057771C/zh not_active Expired - Lifetime
- 1994-09-16 RO RO96-00537A patent/RO117455B1/ro unknown
- 1994-09-16 HU HU9600656A patent/HU220060B/hu unknown
- 1994-09-16 SK SK347-96A patent/SK281869B6/sk unknown
- 1994-09-16 WO PCT/US1994/010530 patent/WO1995007927A1/en not_active Ceased
- 1994-09-16 PL PL94313492A patent/PL180002B1/pl unknown
- 1994-09-16 SG SG1996007353A patent/SG52650A1/en unknown
- 1994-09-16 HR HR940563A patent/HRP940563B1/xx not_active IP Right Cessation
- 1994-09-16 ES ES94929828T patent/ES2113127T3/es not_active Expired - Lifetime
- 1994-09-16 EP EP94929828A patent/EP0719278B1/en not_active Expired - Lifetime
- 1994-09-16 KR KR1019960701363A patent/KR100364953B1/ko not_active Expired - Lifetime
- 1994-10-10 SA SA94150231A patent/SA94150231B1/ar unknown
1995
- 1995-03-16 US US08/405,120 patent/US5565467A/en not_active Expired - Lifetime
1996
- 1996-03-08 BG BG100410A patent/BG62363B1/bg unknown
- 1996-03-13 OA OA60795A patent/OA10575A/en unknown
- 1996-03-15 FI FI961231A patent/FI115216B/fi not_active IP Right Cessation
- 1996-03-15 NO NO961080A patent/NO306117B1/no not_active IP Right Cessation
- 1996-08-22 US US08/708,167 patent/US5846976A/en not_active Expired - Lifetime
1997
- 1997-04-23 BR BR1100329-4A patent/BR1100329A/pt active IP Right Grant
1998
- 1998-02-12 GR GR980400317T patent/GR3026144T3/el unknown
2001
- 2001-01-03 CY CY0100002A patent/CY2219B1/xx unknown
2003
- 2003-03-07 NO NO2003003C patent/NO2003003I2/no unknown
- 2003-03-31 NL NL300122C patent/NL300122I2/nl unknown
- 2003-06-18 LU LU91027C patent/LU91027I2/fr unknown
2004
- 2004-07-26 CY CY200400002C patent/CY2004002I2/el unknown

Also Published As

Publication number	Publication date
CZ286069B6 (cs)	2000-01-12
SG52650A1 (en)	1998-09-28
DE10399022I1 (de)	2004-01-15
PL313492A1 (en)	1996-07-08
HUT73850A (en)	1996-09-30
SI0719278T1 (sl)	1998-06-30
ES2113127T3 (es)	1998-04-16
AP494A (en)	1996-05-15
EP0719278A1 (en)	1996-07-03
HRP940563A2 (en)	1997-02-28
CN1057771C (zh)	2000-10-25
NO2003003I2 (no)	2007-06-11
BG100410A (bg)	1996-09-30
RO117455B1 (ro)	2002-03-29
ZA947118B (en)	1995-05-26
SK34796A3 (en)	1996-07-03
IS1713B (is)	1998-12-30
CY2219B1 (en)	2003-04-18
CZ74596A3 (en)	1996-09-11
SK281869B6 (sk)	2001-08-06
NZ274642A (en)	1997-11-24
RU2140926C1 (ru)	1999-11-10
DE69407978T2 (de)	1998-05-07
CA2170047C (en)	2004-11-09
AU7875194A (en)	1995-04-03
CA2170047A1 (en)	1995-03-23
CY2004002I1 (el)	2009-11-04
US5565467A (en)	1996-10-15
HRP940563B1 (en)	2000-10-31
NO961080D0 (no)	1996-03-15
BR1100329A (pt)	2000-06-13
SA94150231B1 (ar)	2005-05-04
NL300122I2 (nl)	2003-09-01
FI961231L (fi)	1996-03-15
OA10575A (en)	2002-06-25
IL110978A (en)	1999-01-26
PL180002B1 (pl)	2000-11-30
GR3026144T3 (en)	1998-05-29
DK0719278T3 (da)	1998-09-14
LU91027I2 (fr)	2004-04-28
DE69407978D1 (de)	1998-02-19
FI115216B (fi)	2005-03-31
US5846976A (en)	1998-12-08
KR100364953B1 (ko)	2003-04-08
NO961080L (no)	1996-03-15
HU220060B (hu)	2001-10-28
FI961231A0 (fi)	1996-03-15
NO306117B1 (no)	1999-09-20
PE15095A1 (es)	1995-06-04
AU690925B2 (en)	1998-05-07
CA2462061A1 (en)	1995-03-23
IL110978A0 (en)	1994-11-28
DE10399022I2 (de)	2012-09-13
JPH09502731A (ja)	1997-03-18
NL300122I1 (nl)	2003-06-02
EE03241B1 (et)	1999-12-15
WO1995007927A1 (en)	1995-03-23
ATE162199T1 (de)	1998-01-15
CY2004002I2 (el)	2009-11-04
HK1004334A1 (zh)	1998-11-20
JP2904310B2 (ja)	1999-06-14
AP9400669A0 (en)	1994-10-31
MY119778A (en)	2005-07-29
BG62363B1 (bg)	1999-09-30
EP0719278B1 (en)	1998-01-14
CN1131424A (zh)	1996-09-18
ZA947119B (en)	1995-05-26
IS4205A (is)	1995-03-18
HU9600656D0 (en)	1996-05-28

Publication	Publication Date	Title
TW369521B (en)	1999-09-11	Androstenone derivative
ZA948669B (en)	1995-07-04	New pyrazine carboxamide derivatives the preparation thereof and their use in pharmaceutical compositions
NZ514711A (en)	2004-02-27	Compounds useful as anti-inflammatory agents
NZ247201A (en)	1996-05-28	Substituted sulphonylamido- or sulphonamidocarbonyl-pyridine-2-carboxamide derivatives and pharmaceutical compositions
NZ284846A (en)	1998-12-23	1-substituted-pyrazolo[3,4-b]pyridin-5-carboxylic acid derivatives, preparation, use, intermediates and pharmaceutical compositions thereof
MY133647A (en)	2007-11-30	Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates
HUP9801240A2 (en)	1999-01-28	Oral compositions
NZ240230A (en)	1993-01-27	Mercaptoacetylamide derivatives; preparation, use and pharmaceutical compositions thereof
DZ2103A1 (fr)	2002-07-22	(Méthylsulfonyl)phenyl-2-(5H)-furannones et tant qu'inhibiteurs de cox-2.
DE69410092D1 (en)	1998-06-10	Phenyl heterocyclen als cyclooxygenase-2 inhibitoren
CA2259621A1 (en)	1997-12-24	Isocoumarin derivatives and their use in medicines
NZ237023A (en)	1993-01-27	17beta-substituted-4-aza-5alpha-androstan-3-ones and pharmaceutical compositions
CA2338600A1 (en)	2000-02-24	Novel thiazolopyrimidine compounds
BG102250A (en)	1999-02-26	The use of marigold-extracted glycosides for the treatment of psoriasis
PL323364A1 (en)	1998-03-30	Bicyclic aromatic compounds
MX9805705A (es)	1998-10-31	Compuestos biaromaticos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
MX9501849A (es)	1997-02-28	Nuevos compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
AU1727797A (en)	1997-08-28	Heterocyclic biaryl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof
DE69715173D1 (en)	2002-10-10	Bisarylcyclobutenderivate als cyclooxygenasehemmer
YU15895A (sh)	1998-05-15	5-vinil i 5-etinil-hinolon karbonske kiseline postupci za njihovo pripremanje kao i njihova upotreba za pripremanje lekova
AU7895994A (en)	1995-06-29	New polycyclic aromatic compounds, pharmaceutical and cosmetic compositions containing them and their uses
NZ234501A (en)	1991-08-27	Hemoregulatory peptides and pharmaceutical compositions containing them
MD502G2 (ro)	1996-11-30	Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
CA2340734A1 (en)	2000-06-22	Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
ITRM910430A1 (it)	1992-12-17	Composizioni farmaceutiche di somatostatina con assorbimento migliorato, loro preparazione e loro impiego